| CARLAT PUBLISHING

Latuda: An Evaluation of Its Usefulness

With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010. Read More

The New Emphasis on Community Functioning in Schizophrenia

Learn about the new emphasis on community functioning for patients with schizophrenia, in an interview with Dost Ongur, MD, PhD, chief of the psychotic disorders division at McLean Hospital and an associate professor of psychiatry at Harvard Medical School. Read More

We’ve known for some time that if your patient has a parental history of a mood disorder or suicide attempt, his or her risk of a suicide attempt increases, and a new study adds some more information that might help us prevent bad outcomes. Read More

In December 2014, the US Food and Drug Administration (FDA) issued a safety announcement warning that the antipsychotic drug ziprasidone (Geodon) has been associated with a rare but potentially fatal skin reaction. Read More

Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)
Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

General Psychiatry
Elvis, Adderall, and a Broken Heart - Part 1
A new medical investigation changes our understanding of Elvis Presley’s untimely death and offer some pearls for modern psychiatric practice.
Listen now